4″-benzoylureido-TSAO derivatives as potent and selective non-nucleoside HCMV inhibitors. Structure-activity relationship and mechanism of antiviral action

Journal of Medicinal Chemistry

Volumn 51, Issue 18, 2008, Pages 5823-5832

  De Castro, Sonia ^a   Peromingo, M Teresa ^a   Naesens, Lieve ^b   Andrei, Graciela ^b   Snoeck, Robert ^b   Balzarini, Jan ^b   Velázquez, Sonsoles ^a   Camarasa, María José ^a  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

2,6 DIAMINOPURINE; 4'' BENZYLUREIDO (TERT BUTYLDIMETHYLSILYL BETA DEXTRO RIBOFURANOSYL) 3' SPIRO 4'' AMINO 1'',2'' OXATHIAZOLE 2'',2'' DIOXIDE DERIVATIVE; 9 (3 HYDROXY 2 PHOSPHONOMETHOXYPROPYL)ADENINE; [1 [2' O (TERT BUTYLDIMETHYLSILYL) 5' O (THEXYLDIMETHYLSILYL)] BETA DEXTRO RIBOFURANOSYL] 3 N METHYLTHYMINE 3' SPIRO 5'' [4 (3 BENZOYLUREIDO) 1'',2'' OXATHIOLE 2'',2'' DIOXIDE; [1 [2',5' BIS O (THEXYLDIMETHYLSILYL) BETA DEXTRO RIBOFURANOSYL] 3 N METHYLTHYMINE] 3' SPIRO 5'' [4'' (3 BENZOYLUREIDO) 1'',2'' OXATHIOLE 2'',2'' DIOXIDE; ACICLOVIR; ADEFOVIR; CIDOFOVIR; DNA POLYMERASE; ENZYME INHIBITOR; FOSCARNET; GANCICLOVIR; UNCLASSIFIED DRUG; UREA DERIVATIVE; VIRUS DNA; ANTIVIRUS AGENT; DRUG DERIVATIVE; THYMIDINE; UREA;

ANTIVIRAL ACTIVITY; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CULTURE; CELL FREE SYSTEM; CYTOMEGALOVIRUS; DNA SYNTHESIS; DRUG MECHANISM; DRUG POTENCY; DRUG SYNTHESIS; ENZYME INHIBITION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN CYTOMEGALOVIRUS; IMMEDIATE EARLY GENE; MURINE CYTOMEGALOVIRUS; NONHUMAN; PROTON NUCLEAR MAGNETIC RESONANCE; STRUCTURE ACTIVITY RELATION; VIRUS INHIBITION; VIRUS MUTANT; VIRUS STRAIN; CELL LINE; CHEMISTRY; DRUG EFFECT; ELECTROSPRAY MASS SPECTROMETRY; MICROBIOLOGICAL EXAMINATION; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY;

ANTIVIRAL AGENTS; CELL LINE; CYTOMEGALOVIRUS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MICROBIAL SENSITIVITY TESTS; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; THYMIDINE; UREA;

EID: 52449126683     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800050t     Document Type: Article

References (23)

1. Pass, R. F. Cytomegalovirus. In Fields Virology, 4th ed.; Lippincott, Williams & Wilkins: Philadelphia, 2001; Vol 2, pp 2675-2705.
2. Trincado, D. E.; Scott, G. M.; White, P. A.; Hunt, C.; Rasmussen, L.; Rawlinson, W. D. Human cytomegalovirus strains associated with congenital and perinatal infections. J. Med. Virol. 2000, 61, 481-487.
3. Yeh, R.; Cohen, D. M. Pharmacology of viral replication. In Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy; Lippincott, Williams & Wilkins: Baltimore, 2004, pp 545-564.
4. Griffiths, P. D. The treatment of cytomegalovirus infection. J. Antimicrob. Chemother. 2002, 49, 243-253.
5. Cvetkovic, R. S.; Wellington, K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs 2005, 65, 859-878.
6. Biron, K. K. Antiviral drugs for cytomegalovirus diseases. Antiviral Res. 2006, 71, 154-163.
7. Villareal, E. C. Current and potential therapies for the treatment of herpes virus infections. Prog. Drug Res. 2003, 60, 263-307.
8. Huang, E.-S. Human cytomegalovirus IV. Specific inhibition of virus induced DNA polymerase activity and viral DNA replication by phosphonoacetic acid. J. Virol. 1975, 16, 1560-1565.
9. Mar, E. C.; Cheng, Y. C.; Huang, E.-S. Effect of 9-(1,3-dihydroxy2- propoxymethyl)guanine on human cytomegalovirus replication in vitro. Antimicrob. Agents Chemother. 1983, 24, 518-521.
10. Mar, E. C.; Chiou, J. F.; Cheng, Y. C.; Huang, E.-S. Inhibition of cellular DNA polymerase alpha and human cytomegalovirus-induced DNA polymerase by the triphosphates of 9-(2-hydroxyethoxymethyl)guanine and 9-(1,3-dihydroxy-2-propoxymethyl)guanine. J. Virol. 1985, 53, 776-780.
11. Baldanti, F.; Gerna, G. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact. J. Antimicrob. Chemother. 2003, 52, 324-330.
12. De Castro, S.; Lobatón, E.; Pérez-Pérez, M. J.; San-Félix, A.; Cordeiro, A.; Andrei, G.; Snoeck, R.; De Clercq, E.; Balzarini, J.; Camarasa, M. J.; Velázquez, S. Novel [2′,5′- bis-O-(tert-butyldimethylsilyl)-β-D-ribofuronosyl] -3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) derivatives with anti-HIV-1 and anti-human cytomegalovirus activity". J. Med. Chem. 2005, 48, 1158-1168.
13. Camarasa, M. J.; San-Félix, A.; Velázquez, A.; Pérez-Pérez, M. J.; Gago, F.; Balzarini, J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top. Med. Chem. 2004, 4, 945-963.
14. De Castro, S.; Lozano, A.; Jimeno, M. L.; Pérez-Pérez, M. J.; San-Félix, A.; Camarasa, M. J.; Velázquez, S. Unprecedented lability of the 5′-O-tert-butyldimethylsilyl group from 3′-spiro-5″-(4″-acylamino-1″,2″-oxathiole- 2″,2″-dioxide) nucleoside derivatives via neighboring group participation of the 4″-acylamino residue. J. Org. Chem. 2006, 71, 1407-1415.
15. Ingate, S.; Pérez-Pérez, M. J.; De Clercq, E.; Balzarni, J.; Camarasa, M. J. Synthesis and anti-HIV-1 activity of novel TSAO-T derivatives modified at the 2′- and 5′-position of the sugar moiety. Antiviral Res. 1995, 27, 281-299.
16. Pérez-Pérez, M. J.; San-Félix, A.; Balzarini, J.; De Clercq, E.; Camarasa, M. J. TSAO analogues. Stereospecific and anti-HIV-1 activity of 1-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β- D-ribofuranoxyl]-3-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide) pyrimidine and pyrimidine-modified nucleosides. J. Med. Chem. 1992, 35, 2988-2995.
17. Chamorro, C.; Pérez-Pérez, M. J.; Rodríguez-Barrios, F.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M. J. Exploring the role of the 5′-position of TSAO-T. Synthesis and anti-HIV evaluation of novel TSAO-T derivatives. Antiviral Res. 2001, 50, 207-222.
18. Velázquez, S.; Chamorro, C.; Pérez-Pérez, M. J.; Alvarez, R.; Jimeno, M. L.; Martín-Domenech, A.; Pérez, C.; Gago, F.; De Clercq, E.; Balzarini, J.; San-Félix, A.; Camarasa, M. J. Abasic analogues of TSAO-T as the first sugar derivatives that specifically inhibit HIV-1 reverse transcriptase. J. Med. Chem. 1998, 41, 4636-4647.
19. Shimizu, N.; Mori, N.; Kuwahara, Y. Simple synthesis of mite pheromone beta-acardial and its analogs in the secretion of Caloglyphus polyphyllae (Acari. Acaridae). Biosci. Biotechnol. Biochem. 2003, 67, 1732-1736.
20. Cihlar, T.; Fuller, M. D.; Cherrington, J. M. Expression of the catalytic subunit (UL54) and the accessory protein (UL44) of human cytomegalovirus DNA polymerase in a coupled in vitro transcription/translation system. Protein Expression Purif. 1997, 11, 209-218.
21. De Bolle, L.; Manichanh, C.; Agut, H.; De Clercq, E.; Naesens, L. Human herpes virus 6 DNA polymerase: enzymatic parameters, sensitivity to ganciclovir and determination of the role of the A961V mutation in HHV-6 ganciclovir resistance. Antiviral. Res. 2004, 64, 17-25.
22. Andrei, G.; Snoeck, R.; Schols, D.; Goubau, P.; Desmyter, J.; De Clercq, E. Comparative activity of selected antiviral compounds against clinical isolates of human cytomegalovirus. Eur. J. Clin. Microbiol. Infect. Dis. 1991, 10, 1026-1033.
23. Snoeck, R.; Andrei, G.; Bodaghi, B.; Lagneaux, L.; Daelemans, D.; De Clercq, E.; Neyts, J.; Schols, D.; Naesens, L.; Michelson, S.; Bron, D.; Otto, M. J.; Bousseau, A.; Nemecek, C.; Roy, C. 2-Chloro-3-pyridin-3-yl-5,6,7,8- tetrahydroindolizine-1-carboxamide (CMV423), a new lead compound for the treatment of human cytomegalovirus infections. Antiviral Res. 2002, 55, 413-424.